# A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

> **NCT04573023** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **JCR Pharmaceuticals Co., Ltd.** · enrollment: 86 (actual)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **DRUG:** JR-141
- **DRUG:** Idursulfase
- **DRUG:** JR-141 or Idursulfase

## Key facts

- **NCT ID:** NCT04573023
- **Lead sponsor:** JCR Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-14
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04573023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04573023, "A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04573023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*